These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Serum amiodarone and desethylamiodarone concentrations following nasogastric versus oral administration. Kotake T; Takada M; Goto T; Komamura K; Kamakura S; Morishita H J Clin Pharm Ther; 2006 Jun; 31(3):237-43. PubMed ID: 16789989 [TBL] [Abstract][Full Text] [Related]
4. Individual variability of amiodarone distribution in plasma and erythrocytes: implications for therapeutic monitoring. Maling TJ; Siebers RW; Burgess CD; Taylor C; Purdie G Ther Drug Monit; 1989; 11(2):121-6. PubMed ID: 2718218 [TBL] [Abstract][Full Text] [Related]
5. Effects of desethylamiodarone on the electrocardiogram in conscious freely moving animals: pharmacokinetic and pharmacodynamic modeling using computer-assisted radio telemetry. Kharidia J; Eddington ND Biopharm Drug Dispos; 1996 Mar; 17(2):93-106. PubMed ID: 8907716 [TBL] [Abstract][Full Text] [Related]
6. Myocardial amiodarone concentrations after short- and long-term treatment in patients with end-stage heart failure. Candinas R; Frielingsdorf J; Ha HR; Carrel T; Turina M; Follath F Eur J Clin Pharmacol; 1998 Jan; 53(5):331-6. PubMed ID: 9516032 [TBL] [Abstract][Full Text] [Related]
7. The relationship between the QT interval and plasma amiodarone concentration in patients on long-term therapy. Burgess CD; Siebers RW; Purdie GL; Taylor C; Maling TJ Eur J Clin Pharmacol; 1987; 33(2):115-8. PubMed ID: 3691605 [TBL] [Abstract][Full Text] [Related]
8. Interrelationships between serum levels of amiodarone, desethylamiodarone, reverse T3 and the QT interval during long-term amiodarone treatment. Baerman JM; Annesley T; DiCarlo LA; Foley MK; Nicklas JM; Crevey BJ; Morady F Am Heart J; 1986 Apr; 111(4):644-8. PubMed ID: 3953386 [TBL] [Abstract][Full Text] [Related]
9. Corneal Densitometry as a Novel Technique for Monitoring Amiodarone Therapy. Alnawaiseh M; Zumhagen L; Zumhagen S; Schulte L; Rosentreter A; Schubert F; Eter N; Mönnig G Ophthalmology; 2016 Nov; 123(11):2294-2299. PubMed ID: 27591052 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and body distribution of amiodarone and desethylamiodarone in rats after oral administration. Plomp TA; Wiersinga WM; Van Rossum JM; Maes RA In Vivo; 1987; 1(5):265-79. PubMed ID: 2979794 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic characteristics of amiodarone in long-term oral therapy in Japanese population. Kashima A; Funahashi M; Fukumoto K; Komamura K; Kamakura S; Kitakaze M; Ueno K Biol Pharm Bull; 2005 Oct; 28(10):1934-8. PubMed ID: 16204949 [TBL] [Abstract][Full Text] [Related]
12. Plasma concentration time course and pharmacological effects of a standardized oral amiodarone dosing regimen in humans. Brennan FJ; Brien JF; Armstrong PW Can J Cardiol; 1991 Apr; 7(3):117-24. PubMed ID: 2044013 [TBL] [Abstract][Full Text] [Related]
13. A Physiologically Based Pharmacokinetic Model of Amiodarone and its Metabolite Desethylamiodarone in Rats: Pooled Analysis of Published Data. Lu JT; Cai Y; Chen F; Jia WW; Hu ZY; Zhao YS Eur J Drug Metab Pharmacokinet; 2016 Dec; 41(6):689-703. PubMed ID: 26254911 [TBL] [Abstract][Full Text] [Related]
14. Adaptation of the QT interval to heart rate changes in isolated perfused guinea pig heart: influence of amiodarone and D-sotalol. Padrini R; Speranza G; Nollo G; Bova S; Piovan D; Antolini R; Ferrari M Pharmacol Res; 1997 May; 35(5):409-16. PubMed ID: 9299203 [TBL] [Abstract][Full Text] [Related]
15. Amiodarone pharmacokinetics in coronary patients: differences between acute and one-month chronic dosing. Poirier JM; Escoubet B; Jaillon P; Coumel P; Richard MO; Cheymol G Eur J Drug Metab Pharmacokinet; 1988; 13(1):67-72. PubMed ID: 3396616 [TBL] [Abstract][Full Text] [Related]
16. Tolvaptan administration does not affect steady state amiodarone concentrations in patients with cardiac arrhythmias. Shoaf SE; Elizari MV; Wang Z; Sekar K; Grinfeld LR; Barbagelata NA; Lerman J; Bramer SL; Trongé J; Orlandi C J Cardiovasc Pharmacol Ther; 2005 Sep; 10(3):165-71. PubMed ID: 16211205 [TBL] [Abstract][Full Text] [Related]
17. Use of population modeling to define rational monitoring of amiodarone hepatic effects. Pollak PT; Shafer SL Clin Pharmacol Ther; 2004 Apr; 75(4):342-51. PubMed ID: 15060512 [TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamic studies of amiodarone and its active N-desethyl metabolite. Nattel S J Cardiovasc Pharmacol; 1986; 8(4):771-7. PubMed ID: 2427817 [TBL] [Abstract][Full Text] [Related]
20. Disposition of amiodarone and its proximate metabolite, desethylamiodarone, in the dog for oral administration of single-dose and short-term drug regimens. Brien JF; Jimmo S; Brennan FJ; Armstrong PW; Abdollah H Drug Metab Dispos; 1990; 18(6):846-51. PubMed ID: 1981527 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]